Medical Condition News

RSS

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.

17 Mar 2010

Research data: WTC collapse caused potentially dangerous heart problems in responders on-site

Researchers from Mount Sinai School of Medicine are presenting more than 20 ground-breaking studies at the American College of Cardiology 59th annual scientific session (ACC.10) in Atlanta. Their research includes data showing that the World Trade Center collapse has caused potentially dangerous heart problems in responders on-site.

17 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Low-income patients with brain tumors are less likely to be referred to specialty hospitals

African-American, Hispanic, and economically disadvantaged patients with brain tumors are significantly less likely to be referred to high-volume hospitals that specialize in neurosurgery than other patients of similar age, the same gender, and with similar comorbidities, according to new research by Johns Hopkins doctors.

17 Mar 2010

RayStation treatment planning system receives FDA marketing clearance

RaySearch Laboratories AB has received FDA 510(k) clearance for its RayStation® treatment planning system.

17 Mar 2010

Patients with chronic conditions need support to re-enter employment

A new study has identified a significant shortfall in patients with life-long but treatable conditions re-entering employment. The research is being presented at the annual Society for Endocrinology BES meeting in Manchester.

17 Mar 2010

Sonic Innovations' moisture-resistant hearing aids outlast competition

Sonic Innovations, the U.S.-based hearing aid manufacturer, recently conducted moisture-resistance tests using two of its products and eight from major competitors. The results? Sonic outlasted its nearest competitor by 44 percent.

17 Mar 2010

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Some of the most controversial issues in urology will be discussed by leading experts during the five-day 25th Annual Congress of the European Association of Urology in the Fira Barcelona congress venue in Barcelona (ES). From April 16 to 20, close to 12,000 participants and 3,000 company representatives are expected to gather in one of the world's biggest annual professional meetings in urology.

17 Mar 2010

Neovasc Reducer three-year follow-up data presented at 2010 ACC annual meeting

Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.

17 Mar 2010

Radiofrequency ablation helps prolong life of colorectal cancer patients

Approximately half of Americans living with colorectal cancer will develop liver metastases at some point during the course of their disease. Radiofrequency ablation, a minimally invasive treatment that applies heat directly in the tumor causing cancer cell death with minimal associated injury to the surrounding healthy liver, contributes to prolongation of their life by nearly three years, note researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Primary results of CABG sub-analysis presented at ACC meeting

AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA™/BRILIQUE™) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.

17 Mar 2010

Colon cancer patients often not treated with recommended level of chemotherapy

New results from a major initiative on the quality of cancer care in the United States show that patients with a common type of colon cancer -- especially older patients -- often are not treated as aggressively with chemotherapy as research shows is necessary to improve survival.

17 Mar 2010

New clinical guidelines: Early diagnosis and treatment of TAD can save lives

When actor John Ritter died suddenly in 2003 from a tear in his thoracic aorta-the large artery that carries blood from the heart to the rest of the body-that tragedy brought attention to a rare but deadly condition that takes the lives of an estimated 10,000 Americans each year.

17 Mar 2010

Sunbeds Bill to prevent under-18s from using tanning salons receives high-profile support

A Bill to prevent under-18s from using tanning salons has cleared its stages in the House of Commons, and will now go for consideration in the House of Lords.

17 Mar 2010

NCCN Guidelines translated into Japanese

The NCCN Clinical Practice Guidelines in Oncology have been further recognized as the global standard in oncology with the announcement that select NCCN Guidelines™ are being translated into Japanese. The Translational Research Informatics Center Foundation for Biomedical Research and Innovation, under the supervision of the Japanese Society for Cancer of the Colon and Rectum, has translated the NCCN Guidelines for Colon Cancer and Rectal Cancer, which are now available online.

17 Mar 2010

Novel procedure opens door to new and future treatment for pancreatic cancer

Pancreatic cancer-known as the most fatal cancer with no known effective treatment-requires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticles-loaded with a therapeutic agent to kill cancer-in a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Bench to Bassinet Program aims to move lab results into clinical practice

To help speed the translation of scientific discoveries into usable treatments in congenital heart disease, the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health launched the Bench to Bassinet Program.

17 Mar 2010

Cancer news coverage should also focus on hospice and end-of-life care

Newspaper and magazine reports about cancer appear more likely to discuss aggressive treatment and survival than death, treatment failure or adverse events, and almost none mention end-of-life palliative or hospice care, according to a report in the March 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

17 Mar 2010

Avedro to acquire Corneal Collagen Crosslinking Phase III study rights from Peschke Meditrade

Avedro, Inc. today announced it has signed a definitive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies of Corneal Collagen Crosslinking for the treatment of progressive keratoconus and post LASIK ectasia. The two randomized, controlled, multi-site clinical trials are designed to assess the safety and efficacy of riboflavin/ultraviolet-A light for halting the progression of these degenerative disorders and the accompanying decline in patient’s visual acuity.

17 Mar 2010

Anti-obesity drugs fail to tackle wider issues of obesity

Scientists at the University of Liverpool argue that anti-obesity drugs fail to provide lasting benefits for health and wellbeing because they tackle the biological consequences of obesity, and not the important psychological causes of overconsumption and weight gain.

17 Mar 2010